Teverelix - CISMeF

Preferred Label : Teverelix;

NCIt synonyms : D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(aminocarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-; Ac-D-Nal-D-cpa-D-pal-ser-tyr-D-hci-leu-lys(ipr)-pro-D-ala-NH2;

NCIt definition : A synthetic decapeptide and antagonist of the naturally occurring gonadotropin-releasing hormone (GnRH), with potential hormone production inhibitory and antineoplastic activities. Upon administration, teverelix directly competes with GnRH for receptor binding in the anterior pituitary gland, thereby inhibiting GnRH receptor signaling. This inhibits the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. In females, this prevents the production of estrogen by the ovaries and may relieve symptoms from sex-hormone dependent diseases.;

UNII : D19V7048JK;

InChIKey : NOENHWMKHNSHGX-IAOPALDYSA-N;

CAS number : 151272-78-5;

Molecule name : EP 24332; ANB019;

Details

Origin ID

C132277;

UMLS CUI

C0249057;

Currated CISMeF NLP mapping
- antarelix [MeSH Supplementary Concept]
- antarelix [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- antarelix [MeSH Supplementary Concept]
- antarelix [MeSH concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Gonadotropin-Releasing Hormone Receptor [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients